A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...

Please provide your email address to receive an email when new articles are posted on . Within the studied cohort, males had a higher IPF death rate than females. Researchers observed eight industries ...

The MarketWatch News Department was not involved in the creation of this content. -- A new pooled analysis of the FIBRONEER(TM)-IPF and FIBRONEER(TM)-ILD trials resulted in a nominally significant ...

Winning its second FDA approval this year, Boehringer Ingelheim's oral drug Jascayd is now cleared for use in the U.S. by ...

New findings point to a 6% decrease in mortality risk for each unit increase in body mass index (BMI). In a review of 14 datasets including 2080 patients with IPF, researchers found that their risk of ...

Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...

A novel RTEL1 nonsense mutation was identified in a woman with multigenerational familial pulmonary fibrosis (PF), expanding the genetic spectrum of telomere-related lung disease and underscoring the ...

Following the recent approval of nerandomilast tablets for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, the FDA has approved the medication for progressive pulmonary fibrosis as ...